The ability of the NF-κB inhibitor to decrease TNF expression by macrophages and also inhibit downstream signaling in tumor cells may be a potential mechanism by which NF-κB inhibition improves efficacy of ruxolitinib in combination. This evidence concerns the gene NFKB1 and neoplasm.